Spruce Biosciences (NASDAQ:SPRB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Spruce Biosciences (NASDAQ:SPRB – Free Report) from a strong sell rating to a sell rating in a research report released on Saturday,Wall Street Zen reports.

SPRB has been the subject of a number of other reports. The Goldman Sachs Group raised Spruce Biosciences to an “overweight” rating in a report on Thursday, August 13th. Citizens Jmp set a $143.00 price objective on shares of Spruce Biosciences in a report on Thursday. HC Wainwright reaffirmed a “buy” rating on shares of Spruce Biosciences in a report on Wednesday, August 26th. Citigroup reissued a “market outperform” rating on shares of Spruce Biosciences in a report on Thursday. Finally, Lake Street Capital started coverage on shares of Spruce Biosciences in a report on Thursday, September 17th. They issued a “buy” rating and a $149.00 price objective for the company. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Spruce Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $158.22.

Check Out Our Latest Stock Report on SPRB

Spruce Biosciences Stock Performance

Shares of SPRB opened at $42.25 on Friday. The stock has a market capitalization of $121.26 million, a P/E ratio of -1.25 and a beta of 3.57. Spruce Biosciences has a 12 month low of $38.06 and a 12 month high of $127.90. The firm’s fifty day simple moving average is $46.91 and its two-hundred day simple moving average is $54.09. The company has a current ratio of 4.83, a quick ratio of 9.23 and a debt-to-equity ratio of 0.06.

Spruce Biosciences (NASDAQ:SPRB – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($8.51) EPS for the quarter, missing the consensus estimate of ($5.68) by ($2.83). As a group, analysts predict that Spruce Biosciences will post -28.15 EPS for the current year.

Hedge Funds Weigh In On Spruce Biosciences

Institutional investors have recently modified their holdings of the company. ADAR1 Capital Management LLC raised its position in Spruce Biosciences by 1.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 58,600 shares of the company’s stock worth $3,830,000 after purchasing an additional 600 shares during the period. SkyView Investment Advisors LLC purchased a new stake in Spruce Biosciences in the second quarter worth $162,000. Pale Fire Capital SE bought a new stake in shares of Spruce Biosciences during the 2nd quarter valued at about $206,000. Stempoint Capital LP bought a new stake in Spruce Biosciences during the 1st quarter valued at approximately $416,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Spruce Biosciences during the second quarter valued at approximately $366,000. 91.71% of the stock is currently owned by institutional investors.

Spruce Biosciences Company Profile

(Get Free Report)

Spruce Biosciences is a biotechnology company focused on developing treatments for rare endocrine disorders. The U.S.-based company has concentrated on conditions with limited treatment options and has advanced oral drug candidates through clinical development. Its lead investigational candidate, tildacerfont, is a corticotropin-releasing factor type 1 receptor antagonist that Spruce studied for congenital adrenal hyperplasia, a rare disorder affecting hormone production. The company also evaluated the candidate for other endocrine conditions, including polycystic ovary syndrome.

See Also

Analyst Recommendations for Spruce Biosciences (NASDAQ:SPRB)

Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.